In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  1993-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.37.11.2371PMID 8285620PMCID PMC192394
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.

  1993cited by this paper
• Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis

  1992cited by this paper
• Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program.

  1992cited by this paper
• In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii

  1992cited by this paper
• Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80).

  1992cited by this paper
• Orally administered 566C80 for treatment of ocular toxoplasmosis in a patient with the acquired immunodeficiency syndrome.

  1992cited by this paper
• Recent advances in the search for new drugs for treatment of toxoplasmosis.

  1992cited by this paper
• Synergistic activity of clarithromycin and minocycline in an animal model of acute experimental toxoplasmosis

  1992cited by this paper
• Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis

  1992cited by this paper
• Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii

  1991cited by this paper
• A preliminary evaluation of 566C80 for the treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome.

  1991cited by this paper
• Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men.

  1991cited by this paper
• 566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients.

  1991cited by this paper
• Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis

  1990cited by this paper
• In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice

  1990cited by this paper
• Activity in vitro against Toxoplasma gondii of azithromycin and clarithromycin alone and with pyrimethamine.

  1990cited by this paper
• Enzyme immunoassay to assess effect of antimicrobial agents on Toxoplasma gondii in tissue culture

  1988cited by this paper
• Inhibition of pyrimidine biosynthesis de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone in vitro.

  1985cited by this paper
• Potent and selective hydroxynaphthoquinone inhibitors of mitochondrial electron transport in Eimeria tenella (Apicomplexa: Coccidia).

  1984cited by this paper
• Wellcome Foundation

  1968cited by this paper

• Therapeutic effect of baicalein as an antiparasitic agent against Toxoplasma gondii in vitro and in vivo

  2025cites this paper
• Piceatannol Induces Mitochondrial Dysfunction in Toxoplasma gondii

  2025cites this paper
• Effectiveness of Miltefosine Nanoemulsion Concerning the Treatment of Acute and Chronic Toxoplasmosis: In Vivo Study

  2024cites this paper
• Lipophilic bisphosphonates reduced cyst burden and ameliorated hyperactivity of mice chronically infected with Toxoplasma gondii

  2024cites this paper
• Zinc Oxide and Magnesium-Doped Zinc Oxide Nanoparticles Ameliorate Murine Chronic Toxoplasmosis

  2024influential citation
• Mitochondrial dysfunction induced by bedaquiline as an anti-Toxoplasma alternative

  2023cites this paper
• Design and synthesis of novel bis-pyridinium based-ionic liquids as potent antiparasitic agents

  2023cites this paper
• Mefloquine loaded niosomes as a promising approach for the treatment of acute and chronic toxoplasmosis.

  2022cites this paper
• Effect of HIV aspartyl protease inhibitors on experimental infection with a cystogenic Me49 strain of Toxoplasma gondii

  2021cites this paper
• The quest of the best - A SAR study of trithiolato-bridged dinuclear Ruthenium(II)-Arene compounds presenting antiparasitic properties.

  2021cites this paper
• Anti-Toxoplasma Effect of Hydroalchohlic Extract of Terminalia chebula Retz in Cell Culture and Murine Model

  2021cites this paper
• Toxoplasma animal models and therapeutics

  2020cites this paper
• Human Toxoplasma infection

  2020cites this paper
• Control of human toxoplasmosis.

  2020cites this paper
• The Outcomes of Mesenchymal Stem Cells Therapy for Experimental Toxoplasmosis

  2019cites this paper
• Treatment of toxoplasmosis: Current options and future perspectives

  2019cites this paper
• Sex dichotomy in the course of experimental latent toxoplasmosis.

  2019cites this paper
• Adjunctive bradyzoite-directed therapy for reducing complications of congenital toxoplasmosis.

  2019cites this paper
• Systematic Identification of Thiosemicarbazides for Inhibition of Toxoplasma gondii Growth In Vitro

  2019cites this paper
• Treatment of Toxoplasmosis and Neosporosis in Farm Ruminants: State of Knowledge and Future Trends

  2018cites this paper
• Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice

  2018cites this paper
• The effect of lopinavir/ritonavir and lopinavir/ritonavir loaded PLGA nanoparticles on experimental toxoplasmosis.

  2017cites this paper
• Targeting Toxoplasma gondii CPSF3 as a new approach to control toxoplasmosis

  2017influential citation
• In vitro antagonistic and indifferent activity of combination of 3-deoxyanthocyanidins against Toxoplasma gondii

  2017cites this paper
• Mechanisms of Drug Resistance in Toxoplasma gondii

  2017cites this paper
• THERAPEUTIC EFFECT OF NITAZOXANIDE AND ZINGIBER OFFICINALE IN TREATMENT OF ACUTE TOXOPLASMOSIS GONDII USING MURINE EXPERIMENTAL MODEL By

  2017cites this paper
• In Vivo Efficacy of Drugs against Toxoplasma gondii Combined with Immunomodulators.

  2016cites this paper
• Effects of Thymus vulgaris ethanolic extract on chronic toxoplasmosis in a mouse model

  2016cites this paper
• Molecular Characterisation of Toxoplasma gondii and Development of Diagnostic Assay for Bradyzoites

  2016cites this paper
• In vivo effect of anti-TNF agent (etanercept) in reactivation of latent toxoplasmosis

  2016influential citation
• A Systematic Review and Meta-Analysis of the Efficacy of Anti-Toxoplasma gondii Medicines in Humans

  2015cites this paper
• Triclosan and triclosan-loaded liposomal nanoparticles in the treatment of acute experimental toxoplasmosis.

  2015cites this paper
• Effect of Nigella sativa oil on experimental toxoplasmosis

  2015influential citation
• Ciprofloxacin Derivatives Affect Parasite Cell Division and Increase the Survival of Mice Infected with Toxoplasma gondii

  2015cites this paper
• Could miltefosine be used as a therapy for toxoplasmosis?

  2015cites this paper
• Chapter 7 – Toxoplasma Animal Models and Therapeutics

  2014cites this paper
• A Single-Pot Synthesis of Atovaquone: An Antiparasitic Drug of Choice

  2014cites this paper
• [Effects of atovaquone and astragalus combination on the treatment and IL-2, IL-12, IFN-γ levels on mouse models of acute toxoplasmosis].

  2014cites this paper
• Toxoplasma gondii infection can induce retinal DNA damage: an experimental study.

  2014cites this paper
• Management of Congenital Toxoplasmosis

  2014cites this paper
• Preparation of 131I-Pyrimethamine and evaluation for scintigraphy of experimentally Toxoplasma gondii-infected rats

  2013cites this paper
• Caractérisation par protéomique et transcriptomique des mécanismes de résistance à la sulfadiazine chez Toxoplasma gondii.

  2012cites this paper
• Great efficacy of sulfachloropyrazine-sodium against acute murine toxoplasmosis.

  2012cites this paper
• New naphthoquinones and an alkaloid with in vitro activity against Toxoplasma gondii RH and EGS strains.

  2012cites this paper
• SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood–brain barriers

  2011cites this paper
• Cyclodextrin/poly(anhydride) nanoparticles as drug carriers for the oral delivery of atovaquone

  2011cites this paper
• In Vitro and In Vivo Activities of 1-Hydroxy-2-Alkyl-4 ( 1 H ) Quinolone Derivatives against Toxoplasma gondii

  2009cites this paper
• In Vitro and In Vivo Activities of 1-Hydroxy-2-Alkyl-4(1H)Quinolone Derivatives against Toxoplasma gondii

  2009cites this paper
• The role of apolipoprotein E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis

  2009cites this paper
• Effect of surfactants on the therapeutic efficacy of atovaquone nanosuspensions against acute and reactivated murine toxoplasmosis

  2009influential citation
• In Vitro Susceptibility of Various Genotypic Strains of Toxoplasma gondii to Pyrimethamine, Sulfadiazine, and Atovaquone

  2008cites this paper
• SYNTHESE DE NOUVELLES QUINONES HETEROCYCLIQUES PAR APPLICATION DES REACTIONS DE CYCLOADDITIONS DE DIELS-ALDER ET 1,3-DIPOLAIRE. EVALUATION IN VITRO DE LEUR ACTIVITE SUR TOXOPLASMA GONDII

  2007cites this paper
• Synthesis and in vitro activities of ferrocenic aminohydroxynaphthoquinones against Toxoplasma gondii and Plasmodium falciparum.

  2006cites this paper
• Toxoplasma gondii: in vitro and in vivo activities of the hydroxynaphthoquinone 2-hydroxy-3-(1'-propen-3-phenyl)-1,4-naphthoquinone alone or combined with sulfadiazine.

  2006cites this paper
• Reactivation of Toxoplasma Retinochoroiditis Under Atovaquone Therapy in an Immunocompetent Patient

  2006cites this paper
• Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil.

  2005cites this paper
• Population Pharmacokinetics of Pyrimethamine and Sulfadoxine in Children Treated for Congenital Toxoplasmosis

  2004cites this paper
• Atovaquone Maintenance Therapy Prevents Reactivation of Toxoplasmic Encephalitis in a Murine Model of Reactivated Toxoplasmosis

  2004cites this paper
• Antiparasitic Agent Atovaquone

  2002cites this paper
• Activity of natural and synthetic naphthoquinones against Toxoplasma gondii, in vitro and in murine models of infection.

  2002cites this paper
• Quinonic derivatives active against Toxoplasma gondii

  2002influential citation
• Atovaquone Nanosuspensions Show Excellent Therapeutic Effect in a New Murine Model of Reactivated Toxoplasmosis

  2001cites this paper
• Drugs effective against Toxoplasma gondii . Present status and future perspective

  2000cites this paper
• Evaluation of the Efficacy of Atovaquone Alone or in Combination with Azithromycin against Acute Murine Toxoplasmosis

  2000cites this paper
• Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis.

  1998cites this paper
• Drug Evaluation of Concurrent Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium Complex Infections in a Rat Model

  1998cites this paper
• Experimental infection of nude mice as a model for Sarcocystisneurona-associated encephalitis

  1997cites this paper
• Atovaquone and proguanil for the treatment of malaria in Brazil.

  1997cites this paper
• Clinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: analysis of drug interactions and efficacies

  1997cites this paper
• Effects of 2',3'-dideoxyinosine on Toxoplasma gondii cysts in mice

  1997cites this paper
• Biochemistry of the coccidia.

  1997cites this paper
• Influence of antimicrobial agents on replication and stage conversion of Toxoplasma gondii.

  1996cites this paper
• In-vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum.

  1996cites this paper
• In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii

  1996cites this paper
• Treatment regimens for patients with toxoplasmic encephalitis.

  1996cites this paper
• Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis

  1996cites this paper
• Atovaquone

  1995cites this paper
• Treatment of acute Toxoplasma gondii infections in mice with diclazuril or a combination of diclazuril and pyrimethamine.

  1995cites this paper
• Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice

  1995cites this paper
• Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections.

  1995cites this paper
• In-vitro and in-vivo activities of roxithromycin in combination with pyrimethamine or sulphadiazine against Toxoplasma gondii.

  1995cites this paper
• Calibration of an in vitro assay system using a non-adherent cell line to evaluate the effect of a drug on Toxoplasma gondii.

  1995cites this paper
• Experimental evaluation of combined prophylaxis against murine pneumocystosis and toxoplasmosis.

  1994cites this paper